Dr. Jean-Claude Tardif’s research team at the Montreal Heart Institute (MHI) is looking for people living with type 2 diabetes to participate in the COLCOT-T2D clinical study.
The purpose of the study
The purpose of this study is to determine if an anti-inflammatory agent (colchicine) and an anti-platelet agent (aspirin), combined or alone, can prevent cardiovascular events in type 2 diabetic patients who have never had a cardiovascular event.
The implication
Take the study medication daily, which is delivered to your home every 6 months. Follow-up is done by telephone or video contact, without hospital visits.
The duration
Between 36 and 54 months.
Inclusion criteria
- Living with type 2 diabetes
- Aged between 50 and 80
- Have never suffered a cardiac event
For more information about the study or to participate:
- View the full announcement
- Visitez le site web www.colcot-t2d.org
- Call 1 800-587-3389